4 Value Stocks to Consider Adding to Your Portfolio in Q4

NYSE: HCA | HCA Healthcare, Inc.  News, Ratings, and Charts

HCA – As surging inflation and supply chain disruptions raise concerns over the possibility of a big equity market correction in the near-term, many highly-priced stocks may witness a pullback. Therefore, we think it could be wise to bet on fundamentally sound value stocks HCA Healthcare (HCA), Laboratory Corporation of America (LH), KeyCorp (KEY), and International Paper (IP). Read on.

Although impressive third-quarter corporate earnings, declining jobless claims, and rising consumer spending pushed benchmark indexes to record highs last month, historically-high inflation, the Federal Reserve’s decision to start tapering its bond-buying soon, and ongoing supply chain disruptions have been fostering volatility in the markets of late.

Because highly-priced stocks could suffer a pullback in an anticipated market correction in the near term, value stocks have of late been gaining investors’ good graces. This is evidenced by the iShares Morningstar Value ETF’s (ILCV) 3% returns over the past month.

Therefore, we think it could be rewarding to bet on undervalued stocks HCA Healthcare, Inc. (HCA), Laboratory Corporation of America Holdings (LH), KeyCorp (KEY), and International Paper Company (IP).

HCA Healthcare, Inc. (HCA)

HCA is a Nashville, Tenn.-based health care services company that operates general, acute care hospitals and offers medical and surgical services, medical education, physician resource center, and training programs. As of December 31, 2020, it operated 185 hospitals internationally.

On September 20, 2021, HCA and Steward Health Care, a physician-owned private health care network, signed a definitive agreement that hands over the operations of Steward Health Care’s five Utah hospitals to HCA. Adding these facilities to HCA’s Mountain division network of hospitals should enable HCA to improve healthcare options and meet the increasing demand for healthcare in the Utah region.

For its fiscal third quarter ended September 30, 2021, HCA’s revenues increased 14.8% year-over-year to $15.28 billion. The company’s pre-tax income came in at $3.16 billion, up 219.5% from the prior-year period. Its net income was $2.47 billion for the quarter, marking a 217.3% year-over-year improvement. Its EPS improved 259% year-over-year to $7. The company had $1.03 billion in cash and cash equivalents as of September 30, 2021.

Analysts expect HCA’S EPS to improve 51.7% year-over-year to $17.61 in the current year. A $59.01 billion consensus revenue estimate for the current year represents a 14.5% rise from the prior-year period. It surpassed the Street’s EPS estimates in each of the trailing four quarters. The stock’s EPS is expected to grow at a 15.8% rate per annum over the next five years.

Over the past nine months, the stock has gained 39.3% in price and closed yesterday’s trading session at $243.25.

In terms of forward EV/Sales, HCA is currently trading at 1.88x, which is 70% lower than the 6.28x industry average. In terms of forward EV/EBITDA, HCA is currently trading at 8.79x, which is 47.6% lower than the16.78x industry average.

HCA’s POWR Ratings reflect this promising outlook. The stock has an overall A rating, which equates to Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.

The stock has a B grade for Value, Stability, Sentiment, and Quality. Click here to see the additional ratings for HCA (Growth and Momentum). Of the 13 stocks in the Medical – Hospitals industry, HCA is ranked #1.

Click here to checkout our Healthcare Sector Report for 2021

Laboratory Corporation of America Holdings (LH)

LH is an independent clinical laboratory company that offers a range of clinical laboratory tests and procedures used by the medical profession in core testing, patient diagnosis, and monitoring and treating diseases. It also offers drug development services and provides a range of drug research and development (R&D) and market access services to biopharmaceutical and medical device companies worldwide. LH is headquartered in Burlington, N.C.

On November 18, 2021, LH agreed to acquire Toxikon, a contract research organization that delivers best-in-class nonclinical testing services. This acquisition should  enable LH to create a strategic footprint by partnering with large pharmaceutical companies and biotechnology firms in the Boston area, bolster its strong nonclinical development portfolio, and facilitate entry into medical device investigational device exemption (IDE) submissions.

For the third quarter, ended September 30, 2021, LH’s total revenue increased 4.3% year-over-year to $4.06 billion. The company had $2.04 billion in cash and cash equivalents as of September 30, 2021.

Analysts expect LH’s EPS to improve 13.8% year-over-year to $27.25 for the current year. A $15.89 billion consensus revenue estimate for the current year represents a 13.7% rise from the prior-year period. It surpassed the consensus EPS estimates in each of the trailing four quarters.

LH has gained 18.4% in price over the past nine months and ended yesterday’s trading session at $287.49. LH’s 2.02x forward EV/Sales is 67.9% lower than the 6.28x industry average. In terms of forward EV/EBITDA, LH is currently trading at 7.87x, which is 53.1% lower than the 16.78x industry average.

LH’s POWR Ratings reflect this promising outlook. The stock has an overall B rating, which equates to Buy in our proprietary rating system. LH has an A grade for Sentiment, and a B grade for Value and Quality. Click here to see the additional ratings for LH’s Growth, Momentum, and Stability.

LH is ranked #5 of 54 stocks in the Medical – Diagnostics/Research industry.

Click here to checkout our Healthcare Sector Report for 2021

KeyCorp (KEY)

Cleveland, Ohio-based KEY provides retail and commercial banking, leasing, investment management, and banking products and services to individual, corporate, and institutional clients. In addition, the company offers community development financing, securities underwriting, and brokerage services. As of February 25, 2021, it operated through a network of approximately 1,000 branches and 1,400 ATMs internationally.

On July 16, 2021, KEY expanded its branding relationship with Cardtronics, a leading provider of fully integrated ATM and financial kiosk products and services, and an operator at Kum & Go convenience store locations to enhance KEY’s brand visibility and double its surcharge-free ATM access points in Colorado. KEY is looking forward to gaining immediate scale and offering convenient banking services.

For its fiscal third quarter, ended September 30, 2021, KEY’s total revenue increased 8% year-over-year to $1.82 billion. The company’s income from operations came in at $643 million, indicating a 51.7% increase from the prior-year period. While its net income increased 50.7% year-over-year to $645 million, its EPS grew 58.5% to $0.65.

Analysts expect the stock’s EPS to grow 100% year-over-year to $2.54 in the current year. A $7.14 billion consensus revenue estimate for the current year represents a 6.3% rise from the prior-year period. It surpassed the Street’s EPS estimates in each of the trailing four quarters. Analysts expect the stock’s EPS to grow at a 11.4% rate  per annum over the next five years.

Over the past nine months, KEY has gained 21.5% in price and ended yesterday’s trading session at $23.67. In terms of non-GAAP forward PEG, KEY is currently trading at 0.47x, which is 51.8% lower than the 0.97x industry average. And, in terms of forward Price/Sales, KEY is currently trading at 3.09x, which is 11% lower than the 3.47x industry average.

KEY has a B grade for Value in our proprietary rating system. Click here to see the additional ratings for KEY (Quality, Momentum, Growth, Stability, and Sentiment). The stock is ranked #3 of 11 stocks in the Money Center Banks industry.

International Paper Company (IP)

IP operates as a paper and packaging company internationally that produces renewable fiber-based packaging, pulp, and paper products internationally. The Memphis, Tenn., company operates through three segments–Industrial Packaging; Global Cellulose Fibers; and Printing Papers. It sells its products directly to end-users and converters and through agents, resellers, and paper distributors.

IP’s net sales for its fiscal third quarter, ended September 30, 2021, came in at $5.71 billion, representing an 11.5% rise from the prior-year period. Before income taxes and equity earnings, the company’s earnings came in at $916 million, indicating a 224.8% rise from the prior-year period. IP’s adjusted net earnings were $532 million, up 90% from the prior-year period. And its adjusted EPS increased 90.1% year-over-year to $1.35.

A $4.25 consensus EPS estimate for the current year represents a 51.8% rise from the prior-year period. Its revenue is expected to improve 4.6% year-over-year to $21.53 billion, and its EPS is expected to grow at a 25.8% rate per annum over the next five years.

Over the past nine months, the stock has gained 1.5% in price and ended yesterday’s trading session at $48.57. IP’s 1.19x forward EV/Sales is 35.5% lower than the 1.85x industry average. In terms of forward Price/Sales, IP is currently trading at 0.87x, which is 41.4% lower than the 1.40x industry average.

IP’s POWR Ratings reflect its solid prospects. IP has an A grade for Quality, and a B grade for Growth and Value. In addition to the POWR Ratings grades we have just highlighted, one can see IP’s Momentum, Sentiment, and Stability here.

IP is ranked #4 of 11 stocks in the A-rated Industrial – Paper industry.

Click here to check out our Industrial Sector Report for 2021


HCA shares were trading at $238.47 per share on Friday afternoon, down $4.78 (-1.97%). Year-to-date, HCA has gained 45.98%, versus a 26.74% rise in the benchmark S&P 500 index during the same period.


About the Author: Sweta Vijayan


Sweta is an investment analyst and journalist with a special interest in finding market inefficiencies. She’s passionate about educating investors, so that they may find success in the stock market. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
HCAGet RatingGet RatingGet Rating
LHGet RatingGet RatingGet Rating
KEYGet RatingGet RatingGet Rating
IPGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

7 Simple Strategies to Beat the Market

Steve Reitmeister has been investing successfully for over 40 years. In his new presentation he shares his top 7 strategies learned over the years to help investors beat the stock market (SPY). Discover these strategies now to improve your investing results in the months and years to come.

:  |  News, Ratings, and Charts

AutoNation: A Great Value Stock

Shortages in parts, especially semiconductors, this year, has been a boon to auto dealerships. Consumers resorted to buying used cars and parts, which benefits a company such as AutoNation, Inc. (AN). The stock has seen strong revenue growth and share gains this year. Since AN is still very much undervalued, there is a lot more upside left for investors.

:  |  News, Ratings, and Charts

Go From Zero to 60 with a Still-Early-Stage Stake in Fisker

Admittedly, it took a long time for Fisker (FSR) to unveil its all-electric SUV. With that event now completed, FSR stock is prepped for a rally.

:  |  News, Ratings, and Charts

Bull Market Update: Year End Targets?

4,700 seems to be a point of serious resistance for the S&P (SPY) leading to an extended consolidation period hand in hand with violent sector rotation. Why is this happening? What happens next? And how to trade this environment? The answer to these questions and more are discussed in this market commentary below...

:  |  News, Ratings, and Charts

Go From Zero to 60 with a Still-Early-Stage Stake in Fisker

Admittedly, it took a long time for Fisker (FSR) to unveil its all-electric SUV. With that event now completed, FSR stock is prepped for a rally.

Read More Stories

More HCA Healthcare, Inc. (HCA) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All HCA News